Summary
Adagrasib shows promise in treating KRAS G12C-mutant NSCLC, with lasting responses and potential as a much-needed targeted therapy.
A targeted therapy drug called adagrasib was tested in patients with a certain type of lung cancer called non-small cell lung cancer (NSCLC). The patients had changes in a gene called KRAS G12C.
Adagrasib targets the KRAS G12C gene change to try to stop the cancer. The study results were promising. Over half the patients responded to adagrasib treatment. For some patients, the drug kept working to control their cancer for over 6 months. Others saw their tumors get smaller or stop growing with the drug. This suggests adagrasib has long-lasting effects for some KRAS G12C lung cancer patients.
More research is still needed, but the study shows adagrasib may be an effective new targeted therapy option for NSCLC patients with the KRAS G12C gene change. Since few treatments exist for this group, adagrasib could fill an important need. Further studies will keep evaluating how well and long adagrasib works to help these lung cancer patients.
